Jack Wallace
Stock Analyst at Guggenheim
(3.20)
# 1,074
Out of 4,947 analysts
19
Total ratings
57.89%
Success rate
273.43%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $280.61 | -11.26% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $46.02 | -63.06% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $2.92 | +379.45% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $191.09 | +15.13% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $28.70 | +39.37% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.15 | +1,298.60% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $24.95 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $280.61
Upside: -11.26%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $46.02
Upside: -63.06%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $2.92
Upside: +379.45%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $191.09
Upside: +15.13%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $28.70
Upside: +39.37%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.15
Upside: +1,298.60%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $24.95
Upside: -